Key result
Among older PAD patients stopping antiplatelet therapy, ~66% reinitiate treatment, but over half discontinue again.
Why the study?
Successful treatment of PAD depends on adherence to antiplatelet agents, but rates and predictors of reinitiation and subsequent discontinuation among nonpersistent patients were unclear.
Cohort (n=3,032)
A high rate of 'stop-starting' behavior is observed in older patients with peripheral arterial disease prescribed antiplatelet therapy, with over half of those who reinitiate treatment subsequently discontinuing it again.
Answers are grounded in this paper and cite their sources.
High stop-start antiplatelet patterns signal adherence barriers in older PAD patients; leaves open effects on outcomes.
The successful treatment of peripheral arterial disease (PAD) depends on adequate adherence to medications including antiplatelet agents. The aims of this study were (a) to identify the proportion of nonpersistent patients who reinitiated antiplatelet therapy and how many of them discontinued therapy after reinitiation, and (b) to identify patient- and medication-related characteristics associated with the likelihood of reinitiation and discontinuation among reinitiators. The analysis of reinitiation was conducted on 3032 nonpersistent users of antiplatelet agents aged ≥65 years, with PAD newly diagnosed in 2012. Discontinuation (i.e., a treatment gap of ≥6 months without antiplatelet medication prescription) was analysed in 2006 reinitiating patients. To identify factors associated with the likelihood of reinitiation and discontinuation, Cox regression with time-dependent covariates was used. Reinitiation was recorded in 2006 (66.2%) of 3032 patients who had discontinued antiplatelet medication. Among these 2006 reinitiators, 1078 (53.7%) patients discontinued antiplatelet therapy again. Ischemic stroke and myocardial infarction during nonpersistence and bronchial asthma/chronic obstructive pulmonary disease were associated with an increased likelihood of reinitiation. University education was associated with discontinuation among reinitiators. Factors associated with the probability of reinitiation and discontinuation in reinitiators make it possible to identify older PAD patients in whom "stop-starting" behaviour may be expected.
No takes yet. Share an insight, caveat, or question.
Wawruch et al. (2021) conducted a cohort in Peripheral Arterial Disease (n=3,032). Antiplatelet therapy discontinuation and reinitiation was evaluated on Proportion of nonpersistent patients who reinitiated antiplatelet therapy. Among older patients with peripheral arterial disease who discontinued antiplatelet therapy, 66.2% reinitiated treatment, but 53.7% of these reinitiators subsequently discontinued therapy again.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: